Editor's note

This ExpertREACT article was originally published on 12 March 2009. Research findings and policy positions described reflect the state of knowledge at that date.

The ongoing H5N1 threat

Many experts believe a future influenza pandemic is imminent and poses a continual threat to global human health. H5N1 (avian influenza), with its spread in bird populations across South-East Asia, remained the primary concern at the start of 2009. While total human cases since 2003 were relatively modest at just over 400 with a ~60% case fatality rate, the number of countries reporting H5N1 human cases was growing. The US Department of Health and Human Services (HHS) had allocated approximately $8bn to pandemic preparedness activities since 2004, of which around $4bn was directed to vaccines - covering production capacity expansion, antigen stockpile building and investment in cell-based expression systems.

The key strategic debate VacZine Analytics was tracking through expert interviews and analysis was whether the established reactive approach - wait for a pandemic to emerge, then manufacture and deploy a new vaccine - was viable given its inherent time delays and scale constraints. The alternative concept of pre-emptive or "early" immunological priming proposed dosing populations with candidate pandemic antigens (such as H5N1) in advance to establish immune memory, enabling a rapid response to a subsequent booster dose once a pandemic vaccine was available.

US pandemic preparedness budget (2004-2009)
$8bn
Total HHS budget authority allocated to pandemic preparedness; approximately $4bn directed specifically to vaccine-related activities

The case for priming: expert consensus building

VacZine Analytics' research found the expert community increasingly leaning towards priming as the preferred strategy. The principal objection - that priming with a candidate antigen that might not match the eventual pandemic strain could lead to poor immunological responses - was being addressed by new immunological data suggesting that even partial homology between priming and challenge antigens could be sufficient for meaningful immune memory. While priming raised its own challenges around scale, safety assessment in healthy populations and post-priming surveillance, the conclusion of VacZine Analytics was that the case for priming was growing stronger and deserved more active policy consideration from governments with existing pandemic preparedness frameworks.